Gilead Sciences (GILD) Stock Forecast & Price Target

$78.72

-0.05 (-0.06%)

(As of 09/6/2024 ET)

Gilead Sciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 20 Analyst Ratings

Based on 20 Wall Street analysts who have issued ratings for Gilead Sciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 12 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for GILD.

Consensus Price Target

$82.06
4.24% Upside

High Forecast	$105.00
Average Forecast	$82.06
Low Forecast	$69.00

According to the 20 analysts' twelve-month price targets for Gilead Sciences, the average price target is $82.06. The highest price target for GILD is $105.00, while the lowest price target for GILD is $69.00. The average price target represents a forecasted upside of 4.24% from the current price of $78.72.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	10 Buy rating(s)
Hold	12 Hold rating(s)	12 Hold rating(s)	11 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$82.06	$81.81	$83.69	$90.05
Forecasted Upside	4.24% Upside	17.86% Upside	18.90% Upside	11.71% Upside

Get Gilead Sciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Why billionaires are wiring money to abandoned towns

A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution.

Click here for my exclusive video

GILD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

GILD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Gilead Sciences Stock vs. The Competition

Type	Gilead Sciences	Medical Companies	S&P 500
Consensus Rating Score	2.45	2.77	2.51
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	4.24% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/4/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Sector Perform ➝ Sector Perform	$72.00 ➝ $74.00	-7.15%
8/15/2024	Truist Financial 1 of 5 stars		Boost Target	Hold ➝ Hold	$82.00 ➝ $83.00	+11.98%
8/15/2024	Needham & Company LLC 2 of 5 stars		Reiterated Rating	Hold
8/9/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	U. Raffat Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$70.00 ➝ $70.00	-4.24%
8/9/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$80.00 ➝ $85.00	+12.45%
Get the Latest News and Ratings for GILD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Gilead Sciences and its competitors with MarketBeat's FREE daily newsletter.
7/8/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$93.00	+39.45%
6/20/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$80.00 ➝ $80.00	+15.82%
5/1/2024	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$90.00 ➝ $85.00	+30.37%
4/29/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$80.00 ➝ $76.00	+13.98%
4/26/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$80.00 ➝ $78.00	+19.28%
4/26/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$90.00 ➝ $85.00	+29.99%
4/24/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Reduce ➝ Hold	$69.00	+2.99%
4/19/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$105.00	+58.01%
4/17/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$81.00 ➝ $75.00	+12.06%
3/4/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $77.00	+6.49%
2/22/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$101.00 ➝ $90.00	+24.76%
11/9/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$75.00	-3.72%
10/11/2023	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Graybosch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
9/8/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$88.00 ➝ $95.00	+28.48%
7/24/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight	$105.00 ➝ $100.00	+26.34%
2/10/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$90.00 ➝ $95.00	+11.07%
2/3/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$81.00 ➝ $91.00	+8.23%
12/9/2022	DZ Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$90.00	+0.59%
11/9/2022	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$70.00 ➝ $100.00	+21.61%
11/8/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$80.00 ➝ $90.00	+9.45%
10/28/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$80.00 ➝ $87.00	+11.72%
10/28/2022	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$78.00 ➝ $86.00	+10.44%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:25 PM ET.

GILD Forecast - Frequently Asked Questions

What is Gilead Sciences' forecast for 2024?: According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Gilead Sciences is $82.06, with a high forecast of $105.00 and a low forecast of $69.00.
Should I buy or sell Gilead Sciences stock right now?: 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 12 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" GILD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GILD, but not buy additional shares or sell existing shares.
Does Gilead Sciences's stock price have much upside?: According to analysts, Gilead Sciences's stock has a predicted upside of 16.48% based on their 12-month stock forecasts.
Has Gilead Sciences been upgraded by Wall Street analysts recently?: Over the previous 90 days, Gilead Sciences's stock had 2 upgrades by analysts.
What analysts cover Gilead Sciences?: Gilead Sciences has been rated by research analysts at BMO Capital Markets, Cantor Fitzgerald, Evercore ISI, Needham & Company LLC, Raymond James, Robert W. Baird, Royal Bank of Canada, and Truist Financial in the past 90 days.
Do Wall Street analysts like Gilead Sciences more than its competitors?: Analysts like Gilead Sciences less than other "medical" companies. The consensus rating for Gilead Sciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how GILD compares to other companies.